ABL1 and renal cell carcinoma: The TKIs designed to compete for the ATP binding site of the BCR-ABL fusion protein have been shown to be useful in not only CML but also a variety of other cancers including some non-small-cell lung carcinomas (NSCLC), renal cell carcinomas (RCC), and gastrointestinal stromal tumors (GIST) [6].